13. 多発性硬化症/視神経脊髄炎
[臨床試験数:3,050,薬物数:2,147(DrugBank:348),標的遺伝子数:244,標的パスウェイ数:228

Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
10 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02511028
(ClinicalTrials.gov)
November 27, 201528/7/2015In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance ImagingIn Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance ImagingMultiple SclerosisDrug: FerumoxytolNational Institutes of Health Clinical Center (CC)National Institute of Neurological Disorders and Stroke (NINDS)Completed18 Years70 YearsAll14Phase 1United States
2EUCTR2014-003145-99-GB
(EUCTR)
19/03/201519/01/2015A trial to determine bexarotene's safety and tolerability and it's ability to promote brain repair in patients with multiple sclerosis.A randomised placebo-controlled study of the safety and tolerability of a retinoid-X receptor agonist's ability to promote remyelination in people with relapsing-remitting multiple sclerosis already on interferon-beta therapy: a phase 2a trial - CCMR One Relapsing-remitting multiple sclerosis already on interferon-beta therapy
MedDRA version: 17.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Targretin
Product Name: Bexarotene
INN or Proposed INN: Bexarotene
Cambridge University Hospitals NHS Foundation Trust and the University of CambridgeNULLNot RecruitingFemale: yes
Male: yes
50Phase 2United Kingdom
3NCT02418351
(ClinicalTrials.gov)
February 20158/4/2015A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMSAn Open-label, Non-randomized, Phase I/II Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMSMultiple Sclerosis, Relapsing-RemittingBiological: Autologous Bone Marrow-Derived Mononuclear Stem Cells;Other: Liberation therapyGenesis LimitedNULLTerminated18 Years60 YearsBoth69Phase 1;Phase 2India;Trinidad and Tobago
4NCT02587715
(ClinicalTrials.gov)
February 201526/10/2015A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMSAn Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)Multiple Sclerosis, Relapsing-RemittingBiological: Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells;Other: Liberation therapyNovo Cellular Medicine Institute LLPNULLRecruiting18 Years60 YearsBoth69Phase 1;Phase 2Trinidad and Tobago
5NCT02418325
(ClinicalTrials.gov)
February 20158/4/2015A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMSAn Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)Multiple Sclerosis, Relapsing-RemittingBiological: Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells;Other: Liberation therapyGenesis LimitedNULLTerminated18 Years60 YearsBoth69Phase 1;Phase 2Trinidad and Tobago
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT02587806
(ClinicalTrials.gov)
February 201526/10/2015A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMSAn Open-label, Non-randomized, Phase I/II Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMSMultiple Sclerosis, Relapsing-RemittingBiological: Autologous Bone Marrow-Derived Mononuclear Stem Cells;Other: Liberation therapyNovo Cellular Medicine Institute LLPNULLRecruiting18 Years60 YearsBoth69Phase 1;Phase 2India;Trinidad and Tobago
7NCT02137044
(ClinicalTrials.gov)
July 201422/4/2014Multiple Sclerosis-Collaborative Approach to Rehabilitation Effectiveness StudyImproving the Quality of Care for Pain and Depression in Persons With Multiple SclerosisMultiple Sclerosis;Pain;DepressionBehavioral: Collaborative Care (CC)University of WashingtonPatient-Centered Outcomes Research InstituteCompleted18 YearsN/AAll195N/AUnited States
8NCT01037088
(ClinicalTrials.gov)
December 200917/12/2009Effects of Vaporized Marijuana on Neuropathic PainCCRC: The Analgesic Effect of Vaporized Cannabis on Neuropathic PainNeuropathic Pain;Reflex Sympathetic Dystrophy;Peripheral Neuropathy;Post-herpetic Neuralgia;Spinal Cord Injury;Multiple SclerosisDrug: Mild dose cannabis;Drug: Low dose cannabis;Drug: CannabisUniversity of California, DavisCenter for Medicinal Cannabis Research;VA Northern California Health Care SystemCompleted18 Years70 YearsAll44Phase 1;Phase 2United States
9EUCTR2005-000171-18-FI
(EUCTR)
12/05/200518/04/2005A Multi-center, Open-label Extension Study of the Safety and Tolerability of Long-term Administration of Oral CCI-779 (Temsirolimus) in Subjects with Relapsing Multiple Sclerosis Who Completed Study 3066A2-210-WW - N/AA Multi-center, Open-label Extension Study of the Safety and Tolerability of Long-term Administration of Oral CCI-779 (Temsirolimus) in Subjects with Relapsing Multiple Sclerosis Who Completed Study 3066A2-210-WW - N/A Multiple Sclerosis (Relapsing-remitting MS and Secondary progressive MS with relapses)Product Name: Temsirolimus Tablets
Product Code: CCI-779
INN or Proposed INN: Temsirolimus
Other descriptive name: WAY-130799
Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and DevelopmentNULLNot RecruitingFemale: yes
Male: yes
180Finland
10NCT00228397
(ClinicalTrials.gov)
November 200316/9/2005Study Evaluating CCI-779 in Relapsing Multiple SclerosisA Multicenter, Randomized, Double-blind, Long-term Extension Study to Determine the Safety, Tolerability, and Preliminary Efficacy of CCI-779 in Subjects With Relapsing Multiple Sclerosis.Multiple Sclerosis, Relapsing-RemittingDrug: CCI-779Wyeth is now a wholly owned subsidiary of PfizerNULLCompletedN/AN/ABoth221Phase 2NULL